Document:

Exhibit 10.12

 

TETRALOGIC PHARMACEUTICALS CORPORATION

 

SECOND AMENDED AND RESTATED
 EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of December 17, 2010 by and between John M. Gill, a resident of Berwyn, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”).

 

Background

 

The Employee and the Company are parties to an Amended and Restated Executive Employment Agreement, dated as of October 31, 2006 (the “2006 Employment Agreement”). The Employee and the Company desire to amend and restate the Employment Agreement in accordance with the terms and subject to the conditions contained in this Agreement.

 

IN CONSIDERATION of the foregoing and of the mutual covenants and obligations contained in this Agreement, the Employee and the Company, intending to be legally bound, hereby agree as follows:

 

1.                                      Employment and Term. The parties hereby agree to continue the employment of the Employee as the Company’s President and Chief Executive Officer (such position, referred to herein as the Employee’s “Position”) for a period continuing until December 31, 2011 or the earlier termination of the Employee’s employment in accordance with Section 5 of this Agreement (the “Initial Term”). If on December 31, 2011 or any subsequent anniversary thereof, the Employee is still then an active full-time employee of the Company, the Employee’s employment shall automatically renew for successive renewal terms of one (1) year each unless earlier terminated in accordance with Section 5 of this Agreement (each a “Renewal Term” and together with the Initial Term, the “Term”) unless either the Company or the Employee shall give the other written notice of such party’s intent to not renew such employment at least ninety (90) days prior to the end of the Initial Term or the then applicable Renewal Term. In addition and for no additional consideration, Employee hereby agrees to serve as a member of the Company’s Board of Directors (the “Board”) to the extent elected by the shareholders of the Company and consistent with the by-laws of the Company as they may be amended from time-to-time.

 

2.                                      Duties. During the Term, the Employee shall serve the Company faithfully and to the best of his ability and shall devote substantially all of his business time, attention, skill and efforts to the performance of the duties required by or appropriate for the Position. Subject to the oversight of the Board, the Employee shall (i) have responsibility for the exercise of the executive authority of the Company, being the general and active management of the business of the Company and the carrying into effect of all orders and resolutions of the Board, which executive authority may be delegated by the Employee to other officers and/or employees of the Company, and (ii) such duties and responsibilities as may be assigned to him

 

 

from time to time by the Board. The Employee shall perform such duties and responsibilities at the Company’s facility located in Pennsylvania or at such other location as may be established from time to time by the Company. The Employee, as President and Chief Executive Officer, shall report to the Board.

 

3.                                      Other Business Activities. Except for the business activities set forth on Schedule A or with the prior written consent of the Company in its sole discretion, the Employee will not engage, directly or indirectly, during the Term, in any other business activities or pursuits whatsoever, except activities in connection with charitable or civic activities, personal investments and serving as an executor, trustee or in other similar fiduciary capacity; provided that any such activities do not interfere with the performance of his responsibilities and obligations pursuant to this Agreement.

 

4.                                      Compensation. The Company shall pay the Employee, and the Employee hereby agrees to accept, as compensation for all services to be rendered to the Company and for the Employee’s intellectual property covenants and assignments and covenant not to compete, as provided in the Confidentiality Agreement, as defined in Section 6 hereof, the compensation set forth in this Section 4.

 

4.1.                            Salary. The Company shall continue to pay the Employee a base salary at the annual rate of Four Hundred Thousand One Hundred Ninety Two Dollars ($400,192) (as the same may hereafter be adjusted, the “Salary”) during the Term. The Salary shall be inclusive of all applicable income, social security and other taxes and charges that are required by law to be withheld by the Company (collectively, “Taxes”) and shall be paid and withheld in accordance with the Company’s normal payroll practice for its executive employees from time to time in effect. The Salary shall be subject to increase at the option and in the sole discretion of the Board or the Compensation Committee of the Board (the “Compensation Committee”) based upon the demonstrated performance of the Employee.

 

4.2.                            Bonus. The Employee shall be eligible to be awarded an annual performance bonus of up to thirty-five percent (35%) of Salary paid during the applicable period (“Bonus”), less Taxes, based on the achievement of performance objectives established by the Board for such year. The Employee shall also be eligible to be awarded an additional discretionary bonus for achievements beyond the Board expectations for target performance for such year. Such bonuses shall be determined by the Board or the Compensation Committee and shall be paid within seventy-five (75) days after the conclusion of each year.

 

4.3.                            Equity Participation.

 

(a) New Stock

 

(i)                                New Stock Grant. On or before November 30, 2010, the Company will issue to the Employee (A) an immediately exercisable non-qualified stock option to purchase up to Three Million Eight Hundred Nineteen Thousand Three Hundred Eight (3,819,308) restricted shares of the Company’s common stock, subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, the Company’s

 

2

 

common stock (the “New Stock”), at a per share exercise price equal to Nine Cents ($0.09) per share, subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to, the Company’s common stock (the “Option”), (B) an award of up to such number of restricted shares of New Stock (the “Award”) or (C) a combination of the Option and the Award with respect to, in total, such number of restricted shares of New Stock, as elected by the Employee.

 

The Option and the Award, as applicable, shall be subject to the terms and provisions of the Company’s 2004 Equity Incentive Plan (as amended, the “Plan”) and to the Employee’s execution of a restricted stock agreement and/or a non-qualified stock option agreement which is substantially in the form customarily used by the Company with respect to the issuance of restricted stock or non-qualified stock options, as applicable, under the Plan to the Company’s employees and which contains additional terms not inconsistent with this Section 4.3 or the Plan that are determined to be appropriate by the Board. Shares of New Stock issued pursuant to the Award will be subject to a lapsing right of repurchase by the Company at the original price, if any, paid for such New Stock, which repurchase right will lapse in accordance with the vesting schedule more fully outlined in Section 4.3(a)(ii). The Option will be fully exercisable as of the date the Option is granted for shares of New Stock that are subject to a lapsing right of repurchase by the Company at the original purchase price paid for the New Stock, which repurchase right will also lapse in accordance with the vesting schedule more fully outlined in Section 4.3(a)(ii).

 

(ii)                             New Stock Vesting. The New Stock shall vest in accordance with the following schedule: (A) One Million One Hundred Ninety Three Thousand Five Hundred Thirty One (1,193,531) shares of the New Stock will be immediately vested upon the execution and delivery of the restricted stock agreement and/or non-qualified stock option agreement governing the Award and Option, as applicable; and (B) Two Million Six Hundred Twenty Five Thousand Seven Hundred Seventy Seven (2,625,777) shares of the New Stock shall vest as follows:

 

·                                               Fifty Nine Thousand Six Hundred Seventy Six (59,676) shares shall vest on December 26, 2010, and on the 26th day of the next succeeding 42 calendar months, ending June 26, 2014; and

 

·                                               Fifty Nine Thousand Seven Hundred Nine (59,709) shares shall vest on July 26, 2014;

 

provided, that in each case, the Employee continues to be an active full-time employee of the Company on the applicable vesting date; and provided further, that, if there shall occur a Change in Control (as defined in Section 4.3(c)) prior to the date on which the New Stock is fully vested, then the entire unvested portion of such stock, options or rights shall become immediately vested. In addition, the entire unvested portion of the New Stock shall become immediately vested upon the Employee’s death if the Employee was an active full-time employee of the Company immediately before the Employee’s death.

 

3

 

(b) Allocation of Vesting.  If less than all of the New Stock are issued pursuant to the Award then such Award shall first cover all shares of New Stock, which will be immediately vested upon the execution and delivery of the restricted stock agreement governing the Award and then unvested shares of New Stock in priority of vesting sequence. The Option will provide that a partial exercise of the Option will be deemed to cover first vested shares of New Stock and then unvested shares of New Stock in priority of vesting sequence and that any unvested shares of New Stock purchased upon exercise of the Option shall be subject to the lapsing right of repurchase by the Company in accordance with the vesting schedule outlined in Section 4.3(a)(ii).

 

(c) Change in Control Defined.  For purposes of this Agreement, the restricted stock agreement and/or a non-qualified stock option agreement which implements the issuance of the New Stock, the term “Change in Control” shall mean, for purposes of the provisions of such restricted stock agreement and/or non-qualified stock option agreement which provide for the automatic acceleration of the vesting schedule for any New Stock, the happening of the earliest to occur of the events described in clauses (i), (ii), (iii) and (iv) of the definition of “Change in Control” contained in the Plan, except that, for such purposes, the “Original Issuance Exception” contained in clause (iv) of such definition shall be deemed to apply to original issuances by the Company of shares of its voting capital stock which are approved by at least a majority of the Board.

 

4.4.                            Benefits. The Employee will be entitled to participate in all group life insurance, long-term disability, retirement, vacation and any and all other fringe benefit plans (other than bonus, incentive or equity-based compensation plans that may be sponsored by the Company from time to time) as are from time to time provided by the Company to its executives, subject to the provisions of such plans, including, without limitation, eligibility criteria and contribution requirements, as the same may be in effect from time to time (collectively referred to hereafter as “Benefits”). Notwithstanding the foregoing, the Employee will not be entitled to participate in any medical or dental plan provided by the Company from time to time.

 

4.5.                            Reimbursement of Expenses. During the course of employment, the Employee shall be reimbursed for items of travel, food and lodging and miscellaneous expenses reasonably incurred by him on behalf of the Company, provided that such expenses are incurred, documented and submitted to the Company, all in accordance with the reimbursement policies of the Company as in effect from time to time. The Company shall pay, or reimburse the Employee for, all fees and costs of his legal counsel and accountant in connection with the negotiation and execution of this Agreement and the restricted stock agreement and/or non-qualified stock option agreement contemplated hereby; provided, that the Company’s obligations under this sentence shall not exceed $5,000.

 

5.                                      Early Termination. The Employee’s employment hereunder may be terminated during the Term upon the occurrence of any one of the events described in this Section 5. Upon the effective date of such termination (the “Termination Date”), the Employee shall be entitled only to such compensation and benefits as described in this Section 5.

 

4

 

5.1.                            Termination for Permanent Disability.

 

(a) Without limiting the Company’s right to terminate Employee pursuant to Section 5.2, 5.3 or 5.4 hereof, the Company may terminate the Employee’s employment hereunder at any time as a result of Employee’s Permanent Disability upon written notice to Employee. For purposes of this Agreement, a “Permanent Disability” shall have the same meaning as ascribed to such term (or a term of similar import) in the long-term disability insurance policy maintained by the Company for the Employee’s benefit, or if no such policy exists, shall mean an illness, incapacity or a mental or physical condition that renders the Employee unable or incompetent to carry out the job responsibilities that the Employee held or the tasks that he was assigned at the time the disability commenced for at least 120 consecutive days or for shorter periods totaling 180 days in any twelve-month period, as determined by the Board and supported by the opinion of a physician. The Employee shall fully cooperate with the physician retained to furnish such opinion, including submitting to such examinations and tests as may be requested by the physician.

 

(b) In the event of a termination of Employee’s employment hereunder pursuant to Section 5.1(a), Employee will be entitled to receive all accrued and unpaid (as of the Termination Date) Salary, Benefits and Bonus, including payment prescribed under any disability plan or arrangement provided by the Company in which he is a participant or to which he is a party as an employee of the Company. Except as specifically set forth in this Section 5.1(b), the Company shall have no liability or obligation to Employee for compensation or benefits hereunder by reason of such termination.

 

5.2.                            Termination by Death. In the event that Employee dies during the Term, Employee’s employment hereunder shall be terminated thereby and the Company shall pay to Employee’s executors, legal representatives or administrators an amount equal to all accrued and unpaid (as of the Termination Date) Salary, Benefits and Bonus. Except as specifically set forth in this Section 5.2, the Company shall have no liability or obligation hereunder to Employee’s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through him by reason of Employee’s death, except that Employee’s executors, legal representatives or administrators will be entitled to receive the payment prescribed under any life insurance plan in which he is a participant as an employee of the Company.

 

5.3.                            Termination for Cause; Voluntary Termination.

 

(a) The Company may terminate Employee’s employment hereunder at any time for “Cause” immediately upon written notice to Employee. In addition, the Employee may voluntarily terminate his employment hereunder at any time following sixty (60) days prior written notice to the Board. For purposes of this Agreement, the term “Cause” shall mean, as determined by the Board in its sole discretion: (i) Employee’s failure or refusal to materially perform his duties hereunder or to follow a lawful directive of the Board; (ii) any material breach by the Employee of the terms of this Agreement or the Confidentiality Agreement (as defined below); (iii) other conduct of Employee involving any willful and material misconduct with respect to or against the Company or its property or any of its personnel and which causes material harm to the Company, its property or its personnel; or (iv) Employee being convicted of, or plea of guilty or no contest to, any felony or any crime involving moral turpitude. If termination for Cause is based upon Subsections (i), (ii) or (iii) of

 

5

 

this Subsection (a) and the applicable breach, conduct or violation is capable of being cured, then the Employee shall have thirty (30) days following receipt of written notice to Employee from the Board specifying such failure in reasonable detail to cure such breach, conduct or violation.

 

(b) In the event of a termination of Employee’s employment hereunder pursuant to Section 5.3(a), Employee shall be entitled to receive all accrued but unpaid (as of the Termination Date) Salary and Benefits. All Salary, Benefits and Bonuses shall cease at the time of such termination. Except as specifically set forth in this Section 5.3, the Company shall have no liability or obligation hereunder by reason of such termination.

 

5.4.                            Termination Without Cause; Termination for Good Reason.

 

(a) The Company may terminate Employee’s employment hereunder at any time, for any reason or for no reason, without Cause, effective upon the date designated by the Company upon ninety (90) days prior written notice to Employee. In addition, the Employee may voluntarily terminate his employment for Good Reason (as defined below) following ninety (90) days prior written notice to the Board.

 

(b) Intentionally Omitted.

 

(c) If Employee’s employment is terminated pursuant to Section 5.4(a) at any time during the Term, then Employee shall be entitled to: (i) receive all accrued but unpaid (as of the Termination Date) Salary, Benefits and Bonus and (ii) the Company will continue to pay to the Employee in accordance with the Company’s regular payroll practices his then current Salary in effect on the Termination Date during the twelve (12) month period immediately following the Termination Date, subject to all withholding obligations, calculated on the basis of the Salary in effect at the Termination Date. If the Company shall provide the Employee with notice of the Company’s intention not to renew the Employee’s employment for the upcoming Renewal Term, then the Company shall continue to pay to the Employee in accordance with the Company’s regular payroll practices his then current Salary in effect on the date on which the Initial Term or the then current Renewal Term, as applicable, is scheduled to expire (the “Expiration Date”) during the twelve (12) month period immediately following the Expiration Date, subject to all withholding obligations, calculated on the basis of the Salary in effect at the Expiration Date. The Company’s obligations to pay the amounts outlined in subsection (ii) of the first sentence of this Section 5.4(c) and in the immediately preceding sentence, as applicable, shall be contingent upon the Employee executing and not revoking a release of all claims pursuant to a Separation Agreement and Release substantially in the form attached hereto as Exhibit A. All Benefits and Bonuses shall cease at the time of such termination, subject to the terms of any benefit or compensation plan then in force and applicable to Employee. Except as specifically set forth in this Section 5.4(c), the Company shall have no liability or obligation hereunder by reason of such termination.

 

(d) For purposes of this Agreement, the term “Good Reason” shall mean the earliest to occur of any of the following events that are not consented to by the Employee: (i) any substantial and adverse alteration by the Company of Employee’s functions, duties or responsibilities that is not remedied by the Company within thirty (30) days after receiving notice of such material alteration; or (ii) requiring the Employee to be principally based

 

6

 

(excluding all travel to perform the Employee’s services hereunder) at any office or location the site of which would result in a commuting distance of greater than 50 miles from Berwyn, Pennsylvania; provided, further, that the Employee’s consent to any event which would otherwise constitute “Good Reason” shall be conclusively presumed if the Employee does not exercise his rights hereunder within thirty (30) days of the event.

 

6.                                 Confidentiality Agreement. The Non-Competition, Non-Solicitation and Confidentiality Agreement, dated as of February 2, 2004, between the Company and the Employee (the “Confidentiality Agreement”), shall be amended to delete the reference to the eIF-5A program in Section 4.3.1 thereof. The Employee shall continue to be bound by the Confidentiality Agreement, as so amended, the terms and provisions of which are hereby ratified and confirmed in all respects and incorporated into this Agreement by reference.

 

7.                                 Parachute Provisions. Payments under this Agreement shall be made without regard to whether the deductibility of such payments (or any other payments) would be limited or precluded by Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), and without regard to whether such payments would subject the Employee to the federal excise tax levied on certain “excess parachute payments” under Section 4999 of the Code; provided, however, that if the Total After-Tax Payments (as defined below) would be increased by the limitation or elimination of any amount payable under this Agreement, then the amount payable under this Agreement will be reduced to the extent necessary to maximize the Total After-Tax Payments. The determination of whether and to what extent payments under this Agreement are required to be reduced in accordance with the preceding sentence will be made by the Company’s independent auditors. In the event of any underpayment or overpayment under this Agreement (as determined after the application of this Section 7), the amount of such underpayment or overpayment will be immediately paid by the Company to the Employee or refunded by the Employee to the Company, as the case may be, with interest at the applicable federal rate provided for in Section 7872(f)(2) of the Code. For purposes of this Agreement, “Total After-Tax Payments” means the total of all “parachute payments” (as that term is defined in Section 280G(b)(2) of the Code) made to or for the benefit of the Employee (whether made hereunder or otherwise), after reduction for all applicable federal taxes (including, without limitation, the tax described in Section 4999 of the Code). Notwithstanding the foregoing, if so requested by the Employee, the Company shall use reasonable efforts to obtain the requisite approval by the stockholders of the Company in the manner contemplated by Q&A 7 of Treas. Reg. Section 1.280G, it being understood that the Company does not guarantee that such approval will be obtained. If the Company determines that such approval has been obtained, and such obligations of Q&A 7 of Treas. Reg. Section 1.280G have been met, all payments shall be made to Employee, without reduction.

 

8.                                 Representations, Warranties and Covenants of the Employee.

 

(a)                                 The Employee represents and warrants to the Company that:

 

(i)                                     There are no restrictions, agreements or understandings whatsoever to which the Employee is a party which would prevent or make unlawful the Employee’s execution of this Agreement or the Employee’s employment hereunder,

 

7

 

or which is or would be inconsistent or in conflict with this Agreement or the Employee’s employment hereunder, or would prevent, limit or impair in any way the performance by the Employee of the obligations hereunder; and

 

(ii)                                  The Employee has disclosed to the Company all restraints, confidentiality commitments or other employment restrictions that he has with any other employer, person or entity.

 

(b)                            The Employee covenants that in connection with his provision of services to the Company, he shall not breach any obligation (legal, statutory, contractual or otherwise) to any former employer or other person, including, but not limited to obligations relating to confidentiality and proprietary rights.

 

(c)                             Upon and after his termination or cessation of employment with the Company and until such time as no obligations of the Employee to the Company hereunder exist, the Employee (i) shall provide the Confidentiality Agreement to any prospective employer or other person, entity or association engaged in the Field of Interest (as defined in the Confidentiality Agreement), with whom or which the Employee proposes to be employed, affiliated, engaged, associated or to establish any business or remunerative relationship prior to the commencement thereof and (ii) shall notify the Company of the name and address of any such person, entity or association prior to his employment, affiliation, engagement, association or the establishment of any business or remunerative relationship.

 

9.                                 Survival of Provisions. The provisions of this Agreement set forth in Sections 5 through 21 hereof and all other provisions of this Agreement that are intended to endure beyond the Term shall survive the termination of the Employee’s employment hereunder.

 

10.                          Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and the Employee and their respective successors, executors, administrators, heirs and/or assigns; provided that the Employee shall not make any assignment of this Agreement or any interest herein, by operation of law or otherwise, without the prior written consent of the Company.

 

11.                          Notice. Any notice hereunder by either party shall be given by personal delivery or by sending such notice by certified mail, return-receipt requested, or by overnight courier to the other party at its address set forth below or at such other address designated by notice in the manner provided in this section. Such notice shall be deemed to have been received upon the date of actual delivery if personally delivered, in the case of mailing, two (2) days after deposit with the U.S. mail, or, in the case of overnight courier, on the next business day.

 

	
 
    	
(i)
    	
if to the Company, to:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
TetraLogic Pharmaceuticals Corporation

365 Phoenixville Pike
    
	
 
    	
 
    	
Malvern, Pennsylvania  19355
    
	
 
    	
 
    	
Attention:
    	
Andrew Pecora, M.D.,
    
	
 
    	
 
    	
 
    	
Chairman of the Board
    

 

8

 

	
 
    	
 
    	
with a copy to:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Jeffrey P. Libson, Esquire
    
	
 
    	
 
    	
Pepper Hamilton LLP
    
	
 
    	
 
    	
400 Berwyn Park

899 Cassatt Road

Berwyn, Pennsylvania  19312-1183
    
	
 
    	
 
    	
 
    
	
 
    	
(ii)
    	
if to the Employee, to:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
John M. Gill
    
	
 
    	
 
    	
822 Nathan Hale Road

Berwyn, PA  19312
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
with a copy to:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Kathleen M. Shay, Esquire

Duane Morris LLP
    
	
 
    	
 
    	
30 South 17th Street
    
	
 
    	
 
    	
Philadelphia, PA  19103
    

 

12.                          Entire Agreement; Amendments.

 

(a) This Agreement, the Confidentiality Agreement and the restricted stock agreement(s) and/or nonqualified stock option agreement(s) referred to herein contain the entire agreement and understanding of the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature between the parties hereto relating to the employment of the Employee with the Company (including without limitation, the 2006 Employment Agreement).

 

(b) The Employee hereby acknowledges that (a) the sole shares, options, warrants, exit participation rights and other interests in the equity or any exit participation rights of the Employee with respect to the Company are: (i) Seven Hundred Thousand (700,000) shares of the Company’s common stock issued to the Employee, all of which are fully vested; and (ii) Two Million Eight Hundred Ten Thousand (2,810,000) shares of the Company’s common stock issued to the Employee pursuant to, and as governed by, that certain Restricted Stock Agreement, dated as of March 31, 2007, between the Company and the Employee, as amended by that certain Amendment No. 1 to Restricted Stock Agreement dated the date hereof and (iii) the New Stock contemplated by Section 4.3 of this Agreement; and (b) the Employee has no other rights in the equity of, or to participate in the proceeds of any sale of or other transaction involving, the Company.

 

(c) This Agreement may not be changed or modified, except by an agreement in writing signed by each of the parties hereto.

 

9

 

13.                          Waiver. The waiver of the breach of any term or provision of this Agreement shall not operate as or be construed to be a waiver of any other or subsequent breach of this Agreement.

 

14.                          Governing Authority. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to the principles of conflicts of laws of any jurisdiction. The Employee agrees that the Company shall have the right to commence and maintain an action hereunder in the state and federal courts appropriate for the location at which the Company maintains its corporate offices, and the Employee hereby submits to the jurisdiction and venue of such courts.

 

15.                          Invalidity. If any provision of this Agreement shall be determined to be void, invalid, unenforceable or illegal for any reason, the validity and enforceability of all of the remaining provisions hereof shall not be affected thereby. If any particular provision of this Agreement or the Confidentiality Agreement shall be adjudicated to be invalid or unenforceable, such provision shall be deemed amended to delete therefrom the portion thus adjudicated to be invalid or unenforceable, such amendment to apply only to the operation of such provision in the particular jurisdiction in which such adjudication is made; provided that, if any provision contained in this Agreement or the Confidentiality Agreement shall be adjudicated to be invalid or unenforceable because such provision is held to be excessively broad as to duration, geographic scope, activity or subject, such provision shall be deemed amended by limiting and reducing it so as to be valid and enforceable to the maximum extent compatible with the applicable laws of such jurisdiction, such amendment only to apply with respect to the operation of such provision in the applicable jurisdiction in which the adjudication is made.

 

16.                          Section Headings. The section headings in this Agreement are for convenience only; they form no part of this Agreement and shall not affect its interpretation.

 

17.                          Number of Days. In computing the number of days for purposes of this Agreement, all days shall be counted, including Saturdays, Sundays and legal holidays; provided that, if the final day of any time period falls on a Saturday, Sunday or day which is a legal holiday in the Commonwealth of Pennsylvania, then such final day shall be deemed to be the next day which is not a Saturday, Sunday or legal holiday.

 

18.                          Specific Enforcement; Extension of Period.

 

(a)                                 The Employee acknowledges that the restrictions contained in the Confidentiality Agreement are reasonable and necessary to protect the legitimate interests of the Company and its affiliates and that the Company would not have entered into this Agreement in the absence of such restrictions. The Employee also acknowledges that any breach by him of the Confidentiality Agreement will cause continuing and irreparable injury to the Company for which monetary damages would not be an adequate remedy. The Employee shall not, in any action or proceeding to enforce any of the provisions of this Agreement or the Confidentiality Agreement, assert the claim or defense that an adequate remedy at law exists. In the event of such breach by the Employee, the Company shall have the right to enforce the provisions of the Confidentiality Agreement by seeking injunctive or other relief in any court,

 

10

 

and this Agreement or the Confidentiality Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company.

 

(b)                                 The periods of time set forth in the Confidentiality Agreement shall not include, and shall be deemed extended by, any time required for litigation to enforce the relevant covenant periods, provided that the Company is successful on the merits in any such litigation. The “time required for litigation” is herein defined to mean the period of time from the earlier of the Employee’s first breach of such covenants or service of process upon the Employee through the expiration of all appeals related to such litigation.

 

19.                          Arbitration. Subject to the last sentence of this Section 19, if any dispute arises over the terms of this Agreement between the parties to this Agreement, either Employee or Company may submit the dispute to binding arbitration within thirty (30) days after such dispute arises, to be governed by the evidentiary and procedural rules of the American Arbitration Association (Commercial Arbitration). Employee and Company shall mutually select one (1) arbitrator within ten (10) days after a dispute is submitted to arbitration. In the event that the parties do not agree on the identity of the arbitrator within such period, the arbitrator shall be selected by the American Arbitration Association. The arbitrator shall hold a hearing on the dispute at a location chosen by the Company, which shall be within fifteen (15) miles of the Company’s then current corporate offices, within thirty (30) days after having been selected and shall issue a written opinion within fifteen (15) days after the hearing. The arbitrator shall also decide on the allocation of the costs of the arbitration to the respective parties, but Employee and Company shall each be responsible for paying the fees of their own legal counsel, if legal counsel is obtained. Either Employee or Company, or both parties, may file the decision of the arbitrator as a final, binding and unappealable judgment in a court of appropriate jurisdiction. Notwithstanding the foregoing provisions of this Section 19 to the contrary, matters in which an equitable remedy or injunctive relief is sought by a party, including but not limited to the remedies referred to in Section 18 hereof, shall not be required to be submitted to arbitration, if the party seeking such remedy or relief objects thereto, but shall instead be subject to the provisions of Sections 14 and 18 hereof.

 

20.                          Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument.

 

21.                          Section 409A. All payments to be made upon a termination of employment under this Agreement will only be made upon a “separation from service” within the meaning of Section 409A of the Code. In no event may Employee, directly or indirectly, designate the calendar year of payment. To the maximum extent permitted under Section 409A of the Code and its corresponding regulations, the cash severance benefits payable under the Agreement are intended to meet the requirements of the short-term deferral exemption under Section 409A of the Code and the “separation pay exception” under Treas. Reg. §1.409A-1(b)(9)(iii). For purposes of the application of Treas. Reg. § 1.409A-1(b)(4)(or any successor provision), each payment in a series of payments to Employee will be deemed a separate payment. Notwithstanding anything in the Agreement to the contrary or otherwise, except to the extent any expense, reimbursement or in-kind benefit provided pursuant to the Agreement does not constitute a “deferral of compensation” within the meaning of Section 409A of the Code and

 

11

 

its implementing regulations and guidance, (a) the expenses eligible for reimbursement or in-kind benefits provided to Employee must be incurred during the Term (or applicable survival period), (b) the amount of expenses eligible for reimbursement or in-kind benefits provided to Employee during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to Employee in any other calendar year, (c) the reimbursements for expenses for which Employee is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and (d) the right to payment or reimbursement or in-kind benefits hereunder may not he liquidated or exchanged for any other benefit.

 

[SIGNATURE PAGE FOLLOWS]

 

12

 

IN WITNESS WHEREOF, the parties have caused this Second Amended and Restated Executive Employment Agreement to be executed the day and year first written above.

 

	
 
    	
TETRALOGIC PHARMACEUTICALS CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Andrew Pecora
    
	
 
    	
Andrew Pecora, Chairman of the Board
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ John M. Gill
    
	
 
    	
John M. Gill
    

 

13

 

SCHEDULE A

 

Permitted Business Activities

 

1.                                      Board member of PharmAthene, Inc.

 

2.                                      Advisory Board member of Remcon Plastics, Inc.

 

 

EXHIBIT B

 

Separation Agreement and Release

 

THIS SEPARATION AGREEMENT AND RELEASE (this “Agreement”) is made by and between John M. Gill (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”).

 

WHEREAS, the Employee and the Company entered into a Second Amended and Restated Employment Agreement dated December    , 2010 (the “Employment Agreement”) that sets forth the terms and conditions of the Employee’s employment with the Company, including the circumstances under which the Employee is eligible to receive severance pay.

 

NOW, THEREFORE, the Employee and the Company each intending to be legally held bound, hereby agree as follows:

 

1.                                      Consideration. In consideration for a release of claims and other promises and covenants set forth herein, the Company agrees to pay the Employee such consideration as is specified in Section 5.4(c) of the Employment Agreement in accordance with the terms and conditions of the Employment Agreement.

 

2.                                      Employee’s Release. The Employee on his own behalf and together with his heirs, assigns, executors, agents and representatives hereby generally releases and discharges the Company and its predecessors, successors (by merger or otherwise), parents, subsidiaries, affiliates and assigns, together with each and every of their present, past and future officers, managers, directors, shareholders, members, general partners, limited partners, employees and agents and the heirs and executors of same (herein collectively referred to as the “Releasees”) from any and all suits, causes of action, complaints, obligations, demands, common law or statutory claims of any kind, whether in law or in equity, direct or indirect, known or unknown (hereinafter “Claims”), which the Employee ever had or now has against the Releasees, or any one of them occurring up to and including the date of the this Agreement. Notwithstanding anything herein to the contrary, the Employee’s release is not and shall not be construed as a release of any future claim by the Employee against the Company, to the extent a claim may otherwise exist, for indemnity, contribution or cost of defense in connection with the Employee being made a party to a suit initiated by or on behalf of a third party, which suit is based, in whole or in part, upon the work performed by the Employee for the Company within the scope of the Employee’s position and duties with the Company, or any alleged misconduct by the Employee within the scope of the Employee’s former position and duties as an officer or employee of the Company. This release specifically includes, but is not limited to:

 

a.                                      any and all Claims for wages and benefits including, without limitation, salary, stock options, stock, royalties, license fees, health and welfare benefits, severance pay, vacation pay, and bonuses;

 

 

b.                                      any and all Claims for wrongful discharge, breach of contract, whether express or implied, and Claims for breach of implied covenants of good faith and fair dealing;

 

c.                                       any and all Claims for alleged employment discrimination on the basis of race, color, religion, sex, age, national origin, veteran status, disability and/or handicap, in violation of any federal, state or local statute, ordinance, judicial precedent or Employee order, including but not limited to claims for discrimination under the following statutes: Title VII of the Civil Rights Act of 1964, 42 U.S.C. §2000e et seq.; the Civil Rights Act of 1866, 42 U.S.C. §1981; the Civil Rights Act of 1991; the Age Discrimination in Employment Act, as amended, 29 U.S.C. §621 et  seq.; the Older Workers Benefit Protection Act 29 U.S.C. §§ 623, 626 and 630; the Rehabilitation Act of 1972, as amended, 29 U.S.C. §701 et seq.; the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.; the Family and Medical Leave Act of 1993, 29 U.S.C. §2601, et seq.; the Fair Labor Standards Act, as amended, 29 U.S.C. §201, et seq.; the Fair Credit Reporting Act, as amended, 15 U.S.C. §1681, et seq.; and the Employee Retirement Income Security Act of 1974, as amended, 29 U.S.C. §1000, et seq. (“ERISA”) or any comparable state statute or local ordinance;

 

d.                                      any and all Claims under any federal or state statute relating to employee benefits or pensions;

 

e.                                       any and all Claims in tort, including but not limited to, any Claims for assault, battery, misrepresentation, defamation, interference with contract or prospective economic advantage, intentional or negligent infliction of emotional distress, duress, loss of consortium, invasion of privacy and negligence; and

 

f.                                        any and all Claims for attorneys’ fees and costs.

 

3.                                      Acknowledgment. The Employee understands that the release of Claims contained in this Agreement extends to all of the aforementioned Claims and potential Claims which arose on or before the date of this Agreement, whether now known or unknown, suspected or unsuspected, and that this constitutes an essential term of this Agreement. The Employee further understands and acknowledges the significance and consequences of this Agreement and of each specific release and waiver, and expressly consents that this Agreement shall be given full force and effect to each and all of its express terms and provisions, including those relating to unknown and uncompensated Claims, if any, as well as those relating to any other Claims specified herein. The Employee hereby waives any right or Claim that the Employee may have to employment, reinstatement or re-employment with the Company.

 

4.                                      Confidentiality. The Employee shall not disclose or publicize the terms of this Agreement to any person or entity, except that the Employee may disclose the terms, and/or fact of this Agreement to immediate family members, the Employee’s accountants and attorneys and to others as strictly required by law. The Employee is specifically prohibited from disclosing the fact or terms of this Agreement to any current or former employee of the Releasees. The Employee further agrees that he shall be responsible for the Company’s attorney’s fees and costs, if it needs to file an action to enforce its rights under this paragraph, to the extent permitted by law. In the event that the Employee is requested or required (by oral

 

B-2

 

questions, interrogatories, requests for information or documents in a court or administrative proceeding, subpoena, civil investigative demand or other similar process) to disclose the terms of this Agreement, the Employee will endeavor in good faith to provide the Company prompt notice of any such request or requirement so that the Company may, at the Company’s expense, seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement. If, in the absence of a protective order or other similar remedy or the receipt of a waiver from the Company, the Employee reasonably determines that disclosure of the terms of this Agreement is required to comply with such process or applicable law, the Employee may, without liability under this Agreement, disclose to the appropriate authority only that portion of the information which, on advice of counsel, he reasonably believes he is required to disclose.

 

5.                                      Remedies. All remedies at law or in equity shall be available to the Releasees for the enforcement of this Agreement. This Agreement may be pleaded as a full bar to the enforcement of any Claim that the Employee may assert against the Releasees.

 

6.                                      No Admission. Neither the execution of this Agreement by the Company, nor the terms hereof, constitute an admission by the Company of any liability to the Employee.

 

7.                                      Entire Agreement. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof, and shall be binding upon their respective heirs, executors, administrators, successors and assigns. In the event there is any inconsistency between the terms of this Agreement and the Employment Agreement, the terms of this Agreement shall control.

 

8.                                      Severability. If any term or provision of this Agreement shall be held to be invalid or unenforceable for any reason, then such term or provision shall be ineffective to the extent of such invalidity or unenforceability without invalidating the remaining terms or provisions hereof, and such term or provision shall be deemed modified to the extent necessary to make it enforceable.

 

9.                                      Advice of Counsel; Revocation Period. The Employee is hereby advised to seek the advice of counsel prior to signing this Agreement. The Employee hereby acknowledges that the Employee is acting of his own free will, that he has been afforded a reasonable time to read and review the terms of this Agreement, and that he is voluntarily entering into this Agreement with full knowledge of its provisions and effects. The Employee further acknowledges that he has been given at least TWENTY-ONE (21) days within which to consider this Agreement and that he has SEVEN (7) days following his execution of this Agreement to revoke his acceptance, with this Agreement not becoming effective until the 7-day revocation period has expired. If the Employee elects to revoke his acceptance of this Agreement, the Employee must provide written notice of such revocation by certified mail (postmarked no later than seven days after the date the Employee accepted this Agreement) to:

 

B-3

 

Andrew Pecora

TetraLogic Pharmaceuticals Corporation

365 Phoenixville Pike

Malvern, Pennsylvania 19355

Attention: Chairman of the Board

Telecopier: (610) 889-9994

 

with a copy to:

 

Jeffrey P. Libson, Esquire

Pepper Hamilton LLP

400 Berwyn Park

899 Cassatt Road

Berwyn, Pennsylvania 19312-1183

Telecopier:  (610) 640-7835

 

10.                               Employee’s Representation. The Employee represents and warrants that he has not assigned any claim that he purports to release hereunder and that he has the full power and authority to enter into this Agreement and bind each of the persons and entities that the Employee purports to bind. The Employee further represents and warrants that he is bound by, and agrees to remain bound by, his post-employment obligations set forth in the Employment Agreement.

 

11.                               Amendments. Neither this Agreement nor any term hereof may be changed, waived, discharged, or terminated, except by a written agreement signed by the parties hereto.

 

12.                               Governing Authority. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to the principles of conflicts of laws of any jurisdiction. The Employee agrees that the Company shall have the right to commence and maintain an action hereunder in the state and federal courts appropriate for the location at which the Company maintains its corporate offices, and the Employee hereby submits to the jurisdiction and venue of such courts.

 

13.                               Fees and Costs. The parties shall bear their own attorneys’ fees and costs.

 

14.                               Counterparts. This Agreement may be executed in counterparts.

 

15.                               Legally Binding. The terms of this Agreement contained herein are contractual, and not a mere recital.

 

[SIGNATURE PAGE FOLLOWS]

 

B-4

 

IN WITNESS WHEREOF, the Employee, acknowledging that he is acting of his own free will after having had the opportunity to seek the advice of counsel and a reasonable period of time to consider the terms of this Agreement, and the Company, have caused the execution of this Agreement as of this day and year written below.

 

	
 
    	
 
    	
 
    
	
John M. Gill
    	
 
    	
Witness:
    
	
 
    	
 
    	
 
    
	
Date:
    	
 
    	
 
    	
Date:
    	
 
    
	
 
    	
 
    	
 
    
	
TETRALOGIC PHARMACEUTICALS CORPORATION
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Name:
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Title:
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Date:
    	
 
    	
 
    	
 
    

 

B-5Exhibit 10.13

 

 

 

November 13, 2012

 

Richard Sherman

4429 Kaluamakua Place

Kilauea, HI 96754

 

Dear Dick:

 

I am pleased to extend this offer for you to become the Senior Vice President Strategic Transactions and General Counsel of TetraLogic Pharmaceuticals subject to the following terms and conditions:

 

Start Date

 

You will become an employee of the Company on December 1, 2012 (your “Start Date”).

 

Position and Responsibility

 

You will serve as Senior Vice President Strategic Transactions and General Counsel, and act as Secretary of the Company. You will have the duties, responsibilities and authority normally associated with the position. Your employment will be on a part-time basis, expected to average about 20 hours per week and more as needed and you will be a member of the Company’s senior management team and as company General Counsel will participate in Board of Directors meetings.

 

Base Cash Compensation

 

Commencing on your Start Date, you will receive a monthly salary of $16,700 less applicable required withholdings and elected deductions paid semi-monthly.

 

Cash Incentive Compensation

 

Through 2013 you can earn cash bonuses based on the company achieving the following milestones:

 

	
·
    	
SinoLogic closing
    	
$40K
    	
Upon approval of TetraLogic Board
    
	
·
    	
Equity Financing
    	
$80K
    	
$20 million new money to TL
    
	
·
    	
Regional License
    	
$80K
    	
$30M non-dilutive cash within 3 yrs. of signing
    
	
·
    	
TRAIL Agonist Agreement
    	
$25K
    	
Upon approval of TetraLogic Board
    
	
·
    	
Dx Partnering:
    	
$25K
    	
Upon approval of TetraLogic Board
    

 

In the event a particular transaction includes more than one of the components listed above, the bonuses for each included component would apply.

 

343 Phoenixville Pike · Malvern, PA 19355 · P 610.889.9900 · F 610.889.9994
 www.tetralogicpharma.com

 

1

 

Stock Incentive Compensation

 

You will be granted 1,500,000 options to purchase common stock or shares of restricted common stock of the Company (the “Stock”), which are subject to forfeiture until such time as the Stock vests and become nonforfeitable on a ratable basis, as follows:

 

i.                  Standard vesting — 375,000 shares shall vest on March 31, 2013 the first anniversary of when the employee began committing fifty percent (50%) or more of his time to TetraLogic activities. After April 1, 2013 the stock shall vest at the rate of 31,250 per month until all stock is vested. Shares that vest upon accelerated vesting events do not affect the vesting rate of 31,250 per month.

 

ii.               Accelerated vesting of shares shall occur based upon achieving the following:

 

	
·
    	
SinoLogic closing
    	
75,000 shares
    	
 
    	
Board/investors approve terms
    
	
·
    	
Financing 1Q2013
    	
150,000 shares
    	
 
    	
>$20M new money to TL
    
	
·
    	
Regional License Agreement
    	
150,000 shares
    	
 
    	
>$30M non-dilutive cash over 3 Yrs
    
	
·
    	
TRAIL Agonist Agreement
    	
50,000 shares
    	
 
    	
Board/investors approve terms
    
	
·
    	
Dx Partnering Agreement
    	
50,000 shares
    	
 
    	
Board/investors approve terms
    

 

In the event a particular transaction or event includes more than one of the components listed above, the vesting acceleration for each included component would apply.

 

Benefits and Expenses

 

The Company will provide you with the opportunity to participate in the standard benefits plans currently available to other similarly situated employees, including without limitation medical, dental, life and disability insurance, subject to any eligibility requirements imposed by such plans. You have indicated to the Company that you will decline medical and dental coverage benefits. You will be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred by you on behalf of the Company, including airfare (but no other expenses) to and from company headquarters in Malvern, PA, provided such expenses are documented and submitted in accordance with the reimbursement policies in effect from time to time.

 

No Solicitation/Confidentiality

 

As a condition of and prior to the commencement of your employment, you will be expected to abide by Company rules and regulations and fully execute and comply with the Company’s Employee Non-Competition, Non-Solicitation and Confidentiality Agreement (in the form provided by the Company), which prohibits unauthorized use or disclosure of Company proprietary information and certain competitive activities and addresses the Company’s ownership of intellectual property.

 

Termination of Employment

 

You will have the right to terminate your employment hereunder with or without good reason, and the Company will have the right to terminate your employment with or without cause.

 

2

 

I’ll be delighted when you accept our offer and become part of the TetraLogic management team.

 

	
Very truly yours,
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ John M. Gill
    	
 
    
	
John M. Gill
    	
 
    
	
President & Chief Executive Officer
    	
 
    

 

 

	
Acceptance signature:
    	
/s/ Richard Sherman
    	
 
    	
Date: 
    	
11-26-12
    	
 
    
	
 
    	
Richard Sherman
    	
 
    	
 
    

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]